Company Description
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies.
Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Country | United States |
| Founded | 1985 |
| IPO Date | Mar 25, 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 210 |
| CEO | Ronnie Morris |
Contact Details
Address: One University Plaza, Suite 307 Hackensack, New Jersey 07601 United States | |
| Phone | 201 808 8400 |
| Website | championsoncology.com |
Stock Details
| Ticker Symbol | CSBR |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000771856 |
| CUSIP Number | 15870P307 |
| ISIN Number | US15870P3073 |
| Employer ID | 52-1401755 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ronnie Morris M.D. | Chief Executive Officer and Director |
| David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Arthur Hanson | Vice President of Technology |
| Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Karin Abarca Heidemann Ph.D. | Executive Vice President of Global Scientific Operations |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services and Partnering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 10-Q | Quarterly Report |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 27, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 19, 2024 | 10-K | Annual Report |
| Jul 18, 2024 | 8-K | Current Report |